1. Haugen BR. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer 2017;123:372-381.
[CROSSREF]
2. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med 2014;371:1765-1767.
[CROSSREF] [PUBMED]
3. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
[CROSSREF] [PUBMED]
4. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 2009;19:1381-1391.
[CROSSREF] [PUBMED]
5. Jeon MJ, Kim WG, Choi YM, Kwon H, Lee YM, Sung TY, et al. Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid 2016;26:161-168.
[CROSSREF] [PUBMED]
6. Jeon MJ, Kim WG, Kwon H, Kim M, Park S, Oh HS, et al. Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma. Eur J Endocrinol 2017;177:25-31.
[CROSSREF] [PUBMED]
7. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffe S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012;97:1526-1535.
[CROSSREF] [PUBMED] [PDF]
8. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010;20:1235-1245.
[CROSSREF] [PUBMED]
9. Jeon MJ, Lee YM, Sung TY, Han M, Shin YW, Kim WG, et al. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: a cross-sectional study. Thyroid 2019;29:956-962.
[CROSSREF] [PUBMED]
10. Husson O, Haak HR, Buffart LM, Nieuwlaat WA, Oranje WA, Mols F, et al. Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry. Acta Oncol 2013;52:249-258.
[CROSSREF] [PUBMED]
11. Almeida JP, Vartanian JG, Kowalski LP. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch Otolaryngol Head Neck Surg 2009;135:342-346.
[CROSSREF] [PUBMED]
12. Goldfarb M, Casillas J. Thyroid cancer-specific quality of life and health-related quality of life in young adult thyroid cancer survivors. Thyroid 2016;26:923-932.
[CROSSREF] [PUBMED]
13. Sung TY, Shin YW, Nam KH, Chang HS, Rhee Y, Park CS, et al. Psychological impact of thyroid surgery on patients with well-differentiated papillary thyroid cancer. Qual Life Res 2011;20:1411-1417.
[CROSSREF] [PUBMED] [PDF]
14. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV. Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf) 2011;75:544-554.
[CROSSREF] [PUBMED]
15. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
[CROSSREF] [PUBMED]
16. Jeong Y, Choi J, Ahn AL, Oh EJ, Oh HK, Cho DY, et al. Validation of the Korean version of the thyroid cancer-specific quality of life questionnaire. Ann Surg Treat Res 2015;89:287-294.
[CROSSREF] [PUBMED] [PMC]
17. Husson O, Haak HR, Mols F, Nieuwenhuijzen GA, Nieuwlaat WA, Reemst PH, et al. Development of a disease-specific health-related quality of life questionnaire (THYCA-QoL) for thyroid cancer survivors. Acta Oncol 2013;52:447-454.
[CROSSREF] [PUBMED]
18. Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Waadt S, et al. Fear of progression in chronic diseases: psychometric properties of the Fear of Progression Questionnaire. J Psychosom Res 2005;58:505-511.
[CROSSREF] [PUBMED]
19. Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer 2011;2:193-199.
[CROSSREF] [PUBMED] [PMC]
20. Kwon H, Jeon MJ, Kim WG, Park S, Kim M, Kim TY, et al. Lack of efficacy of radioiodine remnant ablation for papillary thyroid microcarcinoma: verification using inverse probability of treatment weighting. Ann Surg Oncol 2017;24:2596-2602.
[CROSSREF] [PUBMED] [PDF]
21. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 2009;71:115-123.
[CROSSREF] [PUBMED]
22. Husson O, Nieuwlaat WA, Oranje WA, Haak HR, van de Poll-Franse LV, Mols F. Fatigue among short- and long-term thyroid cancer survivors: results from the population-based PROFILES registry. Thyroid 2013;23:1247-1255.
[CROSSREF] [PUBMED] [PMC]
23. Hoftijzer HC, Heemstra KA, Corssmit EP, van der Klaauw AA, Romijn JA, Smit JW. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008;93:200-203.
[CROSSREF] [PUBMED] [PDF]
24. Crevenna R, Zettinig G, Keilani M, Posch M, Schmidinger M, Pirich C, et al. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. Support Care Cancer 2003;11:597-603.
[CROSSREF] [PUBMED] [PDF]